Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02701244 · ClinicalTrials.gov registry record
A Registry Study of Breast Microseed Treatment
A clinical trial of Breast Neoplasms, sponsored by Concure Oncology-Breast Microseed.
- Recruiting
- Registry status
- 420
- Enrollment target
- 3
- Study locations
NCT02701244: Recruiting study of Breast Neoplasms, sponsored by Concure Oncology-Breast Microseed.
NCT02701244 is a study of Breast Neoplasms that is actively recruiting participants, run by Concure Oncology-Breast Microseed. The registered enrollment target is 420 participants, below the 565-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (26% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02701244, a study of Breast Neoplasms, is actively recruiting participants, sponsored by Concure Oncology-Breast Microseed.
- RECRUITING
- Registry status
- 420 participants
- Enrollment target
- 3
- Study locations
Study Summary
For women diagnosed with early stage breast cancer, lumpectomy followed by radiation is a common treatment option. Radiation treatment is typically delivered to the whole breast, five times per week, for anywhere from 3 to 8 weeks. The radiation helps kill any cancer cells that may have been left over following the surgery but causes skin burns. Many studies have demonstrated that radiation to the whole breast is not necessary, that it can be delivered to a portion of the breast where the cancer is more likely to recur. A technique called a Permanent Breast Seed Implant (PBSI) involving the implantation of radioactive seeds has been developed to deliver the radiation to a portion of the breast. The procedure is performed on an out-patient basis under local anesthesia and light sedation. Because the radioactive seeds are permanently implanted in the breast, the patient is able to live a normal life while the seeds deliver the prescribed radiation to the breast. Previous studies on PBSI demonstrate that it is a safe and effective alternative form of radiation for appropriately selected patients after lumpectomy. However, those results have been obtained mainly from a single institution, with only 4 patients treated in another center. Further research is still needed to evaluate its safety in a multi-center setting. The purpose of this study is to ensure the appropriate training of clinicians who will be performing this procedure and to capture long term outcomes and rare complications if any.
Conditions Studied
Interventions
- RADIATION Permanent Breast Seed Implant (PBSI)
Study Locations (3)
Pennsylvania
- Allegheny General Hospital - Pittsburgh
Virginia
- Mary Washington Hospital - Fredericksburg
Washington
- Swedish Cancer Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2016-07 |
| Est. Completion | 2026-07 |
What NCT02701244 shows while recruiting
NCT02701244 is an observational study that tracks outcomes without assigning an intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, below the 565-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (26% lower).
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Permanent Breast Seed Implant (PBSI) is the first listed.
NCT02701244 reports a single indexed study location in Pennsylvania, Virginia, Washington.
Frequently Asked Questions
What is clinical trial NCT02701244 about?
NCT02701244 is a clinical study titled "A Registry Study of Breast Microseed Treatment". For women diagnosed with early stage breast cancer, lumpectomy followed by radiation is a common treatment option. Radiation treatment is typically delivered to the whole breast, five times per week, for anywhere from 3 to 8 weeks. The radiation helps kill any cancer cells that may have been left ov...
What is the current status of trial NCT02701244?
This trial is currently recruiting. The enrollment target is 420 participants. The study started on 2016-07. Estimated completion is 2026-07.
What conditions does trial NCT02701244 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT02701244?
The interventions under investigation include: Permanent Breast Seed Implant (PBSI) (RADIATION).
Who is sponsoring clinical trial NCT02701244?
This trial is sponsored by Concure Oncology-Breast Microseed, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02701244 being conducted?
This trial has 3 study locations across Pennsylvania, Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02701244's enrollment target sits among peer trials
420 27th of 97 higher than 71 of 97 other Breast Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RECRUITING · Phase 3
-
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RECRUITING · Phase 3
-
Breast Cancer, Reasoning, and Activity Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
- NCT05097976 · 420 participants · Phase 4
Medrol Dosepak for Outpatient Total Knee Arthroplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia